Literature DB >> 6759078

Metabolic control in 131 juvenile-onset diabetic patients as measured by HbA1c: relation to age, duration, C-peptide, insulin dose, and one or two insulin injections.

G Dahlquist, L Blom, P Bolme, L Hagenfeldt, F Lindgren, B Persson, B Thalme, M Theorell, S Westin.   

Abstract

Glycosylated hemoglobin A (HbA1c), considered to reflect long-term metabolic control of diabetes, was analyzed in 131 patients, aged 2 5/12-19 6/12 yr, with juvenile-onset diabetes. Using stepwise multiple regression HbA1c, fasting blood glucose and plasma 3-hydroxybutyrate were analyzed as dependent variables versus independent variables such as age of the patients, duration of the disease, level of plasma immunoreactive C-peptide (IRCP), insulin dose, and number of insulin injections (one or two) per day. HbA1c was inversely related only to IRCP concentration. A low but significant, positive correlation was found between HbA1c and the duration of diabetes. Stepwise addition of the other independent variables did not further increase the fraction of explained variance. HbA1c was also correlated with a subjective rating score of the metabolic control performed by the treating physician. Fasting plasma glucose was significantly related to HbA1c but not to any of the independent variables. Fasting 3-hydroxybutyrate showed an inverse correlation to the age of the patient. The present study showed that in juvenile-onset diabetic patients, endogenous insulin secretion as reflected by IRCP was the factor best correlated with a low level of HbA1c. After the cessation of endogenous insulin secretion, there is a progressive deterioration of metabolic control and multiple injections of insulin rather than one or two per day may be needed to reach optimal control in the patients.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6759078     DOI: 10.2337/diacare.5.4.399

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  8 in total

1.  Bedtime insulin injections: an alternative regimen.

Authors:  F R Hinde; D I Johnston
Journal:  Arch Dis Child       Date:  1985-04       Impact factor: 3.791

2.  Factors affecting and patterns of residual insulin secretion during the first year of type 1 (insulin-dependent) diabetes mellitus in children.

Authors:  E B Sochett; D Daneman; C Clarson; R M Ehrlich
Journal:  Diabetologia       Date:  1987-07       Impact factor: 10.122

3.  Ketone bodies as markers for type 1 (insulin-dependent) diabetes and their value in the monitoring of diabetic control.

Authors:  Y Harano; K Kosugi; T Hyosu; M Suzuki; H Hidaka; A Kashiwagi; S Uno; Y Shigeta
Journal:  Diabetologia       Date:  1984-05       Impact factor: 10.122

4.  Residual B-cell function in insulin-dependent (type I) diabetics with and without retinopathy.

Authors:  P Sberna; U Valentini; A Cimino; M C Sabatti; A Rotondi; M Crisetig; S Spandrio
Journal:  Acta Diabetol Lat       Date:  1986 Oct-Dec

5.  Failure and efficacy of insulin therapy in insulin dependent (type I) diabetic patients.

Authors:  W Waldhäusl; K Howorka; K Derfler; P R Bratusch-Marrain; C Holler; H Zyman; H Freyler
Journal:  Acta Diabetol Lat       Date:  1985 Oct-Dec

6.  Increased reduction in fasting C-peptide is associated with islet cell antibodies in type 1 (insulin-dependent) diabetic patients.

Authors:  B Marner; T Agner; C Binder; A Lernmark; J Nerup; T Mandrup-Poulsen; S Walldorff
Journal:  Diabetologia       Date:  1985-12       Impact factor: 10.122

7.  The influence of patient variables on insulin total daily dose in paediatric inpatients with new onset type 1 diabetes mellitus.

Authors:  Marion Muller; Benjamin J Wheeler; Miranda Blackwell; Mathilde Colas; David M Reith; Natalie J Medlicott; Hesham S Al-Sallami
Journal:  J Diabetes Metab Disord       Date:  2018-09-17

8.  Twenty-four hour urinary C-peptide and fasting plasma C-peptide as indicators of metabolic control in 83 insulin dependent diabetic patients.

Authors:  H J Yoo; S G Hartling; C Binder
Journal:  Korean J Intern Med       Date:  1987-07       Impact factor: 2.884

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.